Ischemia Induced Obese Individuals Employing Blp 1

Ischemia Induced Obese Individuals Employing BLP1: A Comprehensive Review

Introduction

Obesity has become a major public health concern worldwide, with over 1 billion people affected globally. The consequences of obesity extend beyond physical comorbidities, encompassing cardiovascular diseases, type 2 diabetes, and mortality. In this context, understanding the relationship between obesity, ischemia, and bladder lipase 1 (BLP1) is crucial. This review aims to discuss ischemia-induced obese individuals employing BLP1, exploring its effects on the cardiovascular and metabolic systems.

Background

Ischemia Induced Obese Individuals Employing Blp 1

Obesity has been linked to various cardiovascular diseases, including coronary artery disease, heart failure, and cardiac ischemia. Ischemia, characterized by reduced blood flow to the heart, can lead to tissue damage and cardiac dysfunction. The relationship between obesity, ischemia, and BLP1 remains poorly understood, and research in this area is essential for developing effective therapeutics for the management of obesity-related cardiovascular diseases.

BLP1 as a Therapeutic Target

BLP1, a novel enzyme isolated from the bovine stomach, has been identified as a key player in the development of cardiovascular diseases. Its upregulation in obese individuals can lead to alterations in cardiac function, potentially exacerbating ischemia-related cardiac damage. This raises the question of whether employing BLP1 can mitigate ischemia-induced cardiac dysfunction in obese individuals.

📁 Category: Gallery

🏷️ Tags: #ischemia induced obese individuals employing blp 1 #ischemia #induced #obese #individuals #employing #waterproof basement exterior coating #lawn tractor attachments #effects of glp-1 agonist on protein

Gallery Photos

Obesity Alters Molecular and Functional Cardiac Responses to Ischemia ...

This study tested the hypothesis that obesity alters the cardiac response toischemia/reperfusion and/or glucagon like peptide-1 (GLP-1) receptor activation, and that these differences are associated with alterations in theobesecardiac proteome and microRNA (miR) transcriptome. Ossabaw swine were fed normal chow or obesogenic diet for 6 months.

source: https://www.ncbi.nlm.nih.gov

Obesity alters molecular and functional cardiac responses to ischemia ...

New and noteworthy Diet-inducedobesity/metabolic syndrome in swine was associated with altered cardiovascular functional, miR transcriptome, and proteomic response to cardiacischemia/reperfusion. The GLP-1 mimetic Exendin-4 altered functional, miR and protein responses toischemia/reperfusion differently inobeseversus lean swine.

source: https://link.springer.com

Obesity alters molecular and functional cardiac responses to ischemia ...

This study tested the hypothesis that obesity alters the cardiac response toischemia/reperfusion and/or glucagon like peptide-1 (GLP-1) receptor activation, and that these differences are ...

source: https://www.researchgate.net

Cardiometabolic effects of GLP-1 analogs in obese and overweight ...

Nov 1, 2025Previous evidence regarding the cardiovascular effects of GLP-1 receptor agonists (GLP-1a) in overweight orobeseindividualswith established cardiovascular disease remains inconclusive, primarily due to the limited number of randomized clinical trials (RCTs) specifically targeting this population.

source: https://www.sciencedirect.com

GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging ... - MDPI

Mar 26, 2025Coronary microvascular dysfunction (CMD) is a key contributor to myocardialischemiaand adverse cardiovascular outcomes, particularly inindividualswith metabolic disorders such as type 2 diabetes (T2D). While conventional therapies primarily target epicardial coronary disease, effective treatments for CMD remain limited. Glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as ...

source: https://www.mdpi.com

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Nontraumatic ...

Jun 5, 2025BACKGROUND: GLP-1RAs (glucagon-like peptide-1 receptor agonists) have consistently demonstrated a protective effect against ischemic stroke. However, whether this benefit also extends to nontraumatic intracerebral hemorrhage (ICH) remains unknown. Given the blood pressure-lowering and anti-inflammatory properties of GLP-1RAs, we aimed to evaluate their potential impact on ICH risk in ...

source: https://www.ahajournals.org

PDFObesity Alters Global Response to Ischemia and Glp-1 Agonism

1related drugs, we first examined the effects of obesity on cardiac function, miR transcriptome, and proteome in response to short durationischemia-reperfusion (I/R). We observed divergent physiologic responses (e.g. increased diastolic volume and systolic pressure in lean, decreased diastolic volumes inobese) to

source: https://scholarworks.indianapolis.iu.edu

Cardiometabolic effects of GLP-1 analogs in obese and overweight ...

Apr 29, 2025Efficacy of GLP-1 receptor agonist-based therapies on cardiovascular events and cardiometabolic parameters inobeseindividualswithout diabetes: a meta-analysis of randomized controlled trials

source: https://www.heartandlung.org

GLP1RAs in Clinical Practice: Therapeutic Advances and Safety ...

Apr 15, 2024Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for cardiovascular risk reduction and their broader impacts on cardiometabolic health beyond diabetes mellitus management, guided by the latest clinical trial findings and guidelines. Clinicians should be vigilant for gastrointestinal tract adverse effects in patients using GLP1RAs, advising ...

source: https://www.acc.org

GLP-1 Receptor Agonists and Cardiovascular Outcomes in Adults With ...

Jan 1, 2026Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide proven cardiovascular benefits in type 2 diabetes mellitus (T2DM) and heart failure, but their effects in patients with peripheral artery disease (PAD) remain unclear. PAD is common in T2DM and increases the risk of adverse cardiovascular and limb outcomes. This meta-analysis assessed the impact of GLP-1 RAs on cardiovascular and ...

source: https://www.ajconline.org

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of ...

In patients with CCD and frequent angina or severe stress-inducedischemia, referral to ICA or CCTA is an option. 26 For additional recommendations about known obstructive and nonobstructive CAD, suspectedischemia,ischemiawith nonobstructive coronary arteries (INOCA), role of invasive testing, and revascularization, refer to the 2021 AHA/ACC ...

source: https://www.ahajournals.org

pmc.ncbi.nlm.nih.gov

We would like to show you a description here but the site won't allow us.

source: https://pmc.ncbi.nlm.nih.gov

Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight ...

We conclude that the available evidence demonstrates glucagon‐like peptide‐1 receptor agonists should be strongly considered in clinical practice for the treatment of obesity and reduction of CVD risk in people with type 2 diabetes.

source: https://www.ahajournals.org

Management of Critical Limb Ischemia | Circulation: Cardiovascular ...

Critical limbischemia(CLI) is a clinical syndrome of ischemic pain at rest or tissue loss, such as nonhealing ulcers or gangrene, related to peripheral artery disease. CLI has a high short-term risk of limb loss and cardiovascular events. Noninvasive or invasive angiography help determine the feasibility and approach to arterial revascularization. An endovascular-first approach is often ...

source: https://www.ahajournals.org

National Center for Biotechnology Information

We would like to show you a description here but the site won't allow us.

source: https://pmc.ncbi.nlm.nih.gov

Peri-operative management of the obese surgical patient 2015

Guidelines are presented for the organisational and clinical peri-operative management of anaesthesia and surgery for patients who areobese, along with a summary of the problems that obesity may cause peri-operatively. The advice presented is based on previously published advice, clinical studies and expert opinion.

source: https://associationofanaesthetists-publications.onlinelibrary.wiley.com

GLP-1 COVERAGE | Blue Cross Blue Shield of Massachusetts

Why we've made this change Ending GLP-1 coverage was a difficult, but necessary, decision. The cost of GLP-1sare soaring and, as a not-for-profit organization, we're unable to provide coverage without driving premiums and employer costs even higher. Continued coverage would also be unsustainable for our business. We've approached GLP-1 manufacturers to advocate for lowering prices without ...

source: https://www.bluecrossma.org

Assessment of Myocardial Ischemia in Obese Individuals Undergoing ...

Objective To assess the frequency of myocardialischemiainobeseand non-obesepatients undergoing physical stress echocardiography and compare their clinical and echocardiographic differences.

source: https://www.ncbi.nlm.nih.gov

National Center for Biotechnology Information

We would like to show you a description here but the site won't allow us.

source: https://pmc.ncbi.nlm.nih.gov

National Center for Biotechnology Information

We would like to show you a description here but the site won't allow us.

source: https://pmc.ncbi.nlm.nih.gov

National Center for Biotechnology Information

We would like to show you a description here but the site won't allow us.

source: https://pmc.ncbi.nlm.nih.gov

Complex Relationship of Body Mass Index with Mortality in Patients with ...

Introduction The "obesity paradox" emerges from the observation that mortality in patients with hypertension, heart failure,1, 2 and coronary artery disease 3 decreases as their body mass index (BMI) increases, despite the association of obesity with cardiovascular risk factors.

source: https://www.sciencedirect.com

National Center for Biotechnology Information

We would like to show you a description here but the site won't allow us.

source: https://pmc.ncbi.nlm.nih.gov

Obesity and mortality after the first ischemic stroke: Is obesity ...

Background and purpose Obesity is an established risk factor for ischemic stroke but the association of increased body mass index (BMI) with survival after ischemic stroke remains controversial. Many studies have shown that increased BMI has a "protective" effect on survival after stroke while other studies have debunked the "obesity paradox". This study aimed at examining the ...

source: https://journals.plos.org

Stress Cardiac Mri in Morbidly Obese Patients: Real World Data on Image ...

Apr 5, 2024Given the challenges of cardiac stress testing with elevated body mass index (BMI), it remains unclear whether stress cardiac MRI (CMR) for ischemic evaluation in the morbidlyobeseis diagnostically useful.

source: https://www.jacc.org

Efficacy of lifestyle modification combined with GLP-1 receptor ...

Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers inindividualswith overweight or obesity: a systematic review and meta-analysis

source: https://pmc.ncbi.nlm.nih.gov

GLP-1 receptor agonists and obesity care - The BMJ

Dec 13, 2024The need for lifelong support has implications forindividualsand public health More than a billion people worldwide are living with obesity. After many years of failed attempts to support them in losing weight and optimising their health through lifestyle intervention programmes, glucagon-like peptide-1 (GLP-1) receptor agonists are being heralded as a magic bullet for this global problem.1 ...

source: https://www.bmj.com

National Center for Biotechnology Information

We would like to show you a description here but the site won't allow us.

source: https://pmc.ncbi.nlm.nih.gov

Paeoniflorin reduced BLP-induced inflammatory response by inhibiting ...

We first demonstrated thatBLPinduceda rapid release of TNF-α from THP-1 cells after1h incubation withBLP. The peak release was at 4 h, and then TNF-α production decreased slowly within 24 h.

source: https://www.ncbi.nlm.nih.gov

National Center for Biotechnology Information

We would like to show you a description here but the site won't allow us.

source: https://pmc.ncbi.nlm.nih.gov

Ischemia Induced Obese Individuals Employing Blp 1

Comprehensive Insights and Gallery of Ischemia Induced Obese Individuals Employing Blp 1